It is important to highlight that irrespective of the expression status of poor prognostic markers, such as TP53 and IGHV, all four CLL cell lines, as well as all ten patient-derived CLL samples demonstrated an AR+ subpopulation that proved to be resistant against pharmacologic inhibition of CDC42 activity. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.